A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015)
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumors|Breast Cancer
Interventions: DRUG: MK-2206|BIOLOGICAL: Trastuzumab|DRUG: Lapatinib
Sponsor: Merck Sharp & Dohme LLC